BACKGROUND: The objective of this study was to examine the predictive value of parameters of 3D (1)H magnetic resonance spectroscopic imaging (MRSI) prior to treatment with radiation/chemotherapy (baseline) and at a postradiation 2-month follow-up (F2mo) in relationship to 6-month progression-free survival (PFS6) and overall survival (OS). METHODS: Sixty-four patients with newly diagnosed glioblastoma multiforme (GBM) being treated with radiation and concurrent chemotherapy were involved in this study. Evaluated were metabolite indices and metabolite ratios. Logistic linear regression and Cox proportional hazards models were utilized to evaluate PFS6 and OS, respectively. These analyses were adjusted by age and MR scanner field strength (1.5 T or 3 T). Stepwise regression was performed to determine a subset of the most relevant variables. RESULTS: Associated with shorter PFS6 were a decrease in the ratio of N-acetyl aspartate to choline-containing compounds (NAA/Cho) in the region with a Cho-to-NAA index (CNI) >3 at baseline and an increase of the CNI within elevated CNI regions (>2) at F2mo. Patients with higher normalized lipid and lactate at either time point had significantly worse OS. Patients who had larger volumes with abnormal CNI at F2mo had worse PFS6 and OS. CONCLUSIONS: Our study found more 3D MRSI parameters that predicted PFS6 and OS for patients with GBM than did anatomic, diffusion, or perfusion imaging, which were previously evaluated in the same population of patients.
BACKGROUND: The objective of this study was to examine the predictive value of parameters of 3D (1)H magnetic resonance spectroscopic imaging (MRSI) prior to treatment with radiation/chemotherapy (baseline) and at a postradiation 2-month follow-up (F2mo) in relationship to 6-month progression-free survival (PFS6) and overall survival (OS). METHODS: Sixty-four patients with newly diagnosed glioblastoma multiforme (GBM) being treated with radiation and concurrent chemotherapy were involved in this study. Evaluated were metabolite indices and metabolite ratios. Logistic linear regression and Cox proportional hazards models were utilized to evaluate PFS6 and OS, respectively. These analyses were adjusted by age and MR scanner field strength (1.5 T or 3 T). Stepwise regression was performed to determine a subset of the most relevant variables. RESULTS: Associated with shorter PFS6 were a decrease in the ratio of N-acetyl aspartate to choline-containing compounds (NAA/Cho) in the region with a Cho-to-NAA index (CNI) >3 at baseline and an increase of the CNI within elevated CNI regions (>2) at F2mo. Patients with higher normalized lipid and lactate at either time point had significantly worse OS. Patients who had larger volumes with abnormal CNI at F2mo had worse PFS6 and OS. CONCLUSIONS: Our study found more 3D MRSI parameters that predicted PFS6 and OS for patients with GBM than did anatomic, diffusion, or perfusion imaging, which were previously evaluated in the same population of patients.
Authors: Susan M Chang; Sarah Nelson; Scott Vandenberg; Soonmee Cha; Michael Prados; Nicholas Butowski; Michael McDermott; Andrew T Parsa; Manish Aghi; Jennifer Clarke; Mitchel Berger Journal: J Neurooncol Date: 2009-04-09 Impact factor: 4.130
Authors: P C Sundgren; V Nagesh; A Elias; C Tsien; L Junck; D M Gomez Hassan; T S Lawrence; T L Chenevert; L Rogers; P McKeever; Y Cao Journal: J Magn Reson Imaging Date: 2009-02 Impact factor: 4.813
Authors: Mei-Yin C Polley; Kathleen R Lamborn; Susan M Chang; Nicholas Butowski; Jennifer L Clarke; Michael Prados Journal: Neuro Oncol Date: 2009-12-21 Impact factor: 12.300
Authors: Forrest W Crawford; Inas S Khayal; Colleen McGue; Suja Saraswathy; Andrea Pirzkall; Soonmee Cha; Kathleen R Lamborn; Susan M Chang; Mitchel S Berger; Sarah J Nelson Journal: J Neurooncol Date: 2008-11-15 Impact factor: 4.130
Authors: A P Krishnan; R Karunamuni; K M Leyden; T M Seibert; R L Delfanti; J M Kuperman; H Bartsch; P Elbe; A Srikant; A M Dale; S Kesari; D E Piccioni; J A Hattangadi-Gluth; N Farid; C R McDonald; N S White Journal: AJNR Am J Neuroradiol Date: 2017-03-09 Impact factor: 3.825
Authors: Jayashree Kalpathy-Cramer; Elizabeth R Gerstner; Kyrre E Emblem; Ovidiu Andronesi; Bruce Rosen Journal: Cancer Res Date: 2014-09-01 Impact factor: 12.701
Authors: Yan Li; Peder Larson; Albert P Chen; Janine M Lupo; Eugene Ozhinsky; Douglas Kelley; Susan M Chang; Sarah J Nelson Journal: J Magn Reson Imaging Date: 2014-06-17 Impact factor: 4.813